Capital International Investors lifted its position in BioNTech SE (NASDAQ:BNTX - Free Report) by 38.6% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 1,415,566 shares of the company's stock after buying an additional 394,434 shares during the quarter. Capital International Investors owned about 0.59% of BioNTech worth $161,304,000 as of its most recent SEC filing.
Other institutional investors have also added to or reduced their stakes in the company. FMR LLC boosted its holdings in shares of BioNTech by 22.2% during the 4th quarter. FMR LLC now owns 7,701,476 shares of the company's stock worth $877,583,000 after buying an additional 1,401,547 shares during the period. abrdn plc grew its position in shares of BioNTech by 70.7% in the fourth quarter. abrdn plc now owns 385,668 shares of the company's stock valued at $43,947,000 after purchasing an additional 159,676 shares during the last quarter. Franklin Resources Inc. increased its stake in shares of BioNTech by 3,942.1% during the fourth quarter. Franklin Resources Inc. now owns 136,786 shares of the company's stock worth $15,587,000 after purchasing an additional 133,402 shares during the period. CenterBook Partners LP lifted its holdings in BioNTech by 62.5% during the 4th quarter. CenterBook Partners LP now owns 194,118 shares of the company's stock worth $22,120,000 after purchasing an additional 74,656 shares during the last quarter. Finally, Bank Julius Baer & Co. Ltd Zurich bought a new stake in BioNTech in the 4th quarter valued at $7,128,000. 15.52% of the stock is currently owned by institutional investors and hedge funds.
BioNTech Stock Up 5.0 %
Shares of BioNTech stock traded up $5.71 during trading on Thursday, reaching $120.54. The company's stock had a trading volume of 1,507,853 shares, compared to its average volume of 870,750. The company has a market cap of $28.93 billion, a price-to-earnings ratio of -57.40 and a beta of 1.07. BioNTech SE has a 1-year low of $76.53 and a 1-year high of $131.49. The company has a quick ratio of 7.21, a current ratio of 7.33 and a debt-to-equity ratio of 0.01. The company has a 50-day simple moving average of $102.13 and a two-hundred day simple moving average of $110.78.
BioNTech (NASDAQ:BNTX - Get Free Report) last released its quarterly earnings data on Monday, March 10th. The company reported $1.08 earnings per share for the quarter, topping analysts' consensus estimates of $0.38 by $0.70. The firm had revenue of $1.19 billion for the quarter, compared to analyst estimates of $1.24 billion. BioNTech had a negative net margin of 15.16% and a negative return on equity of 2.35%. The business's quarterly revenue was down 19.5% compared to the same quarter last year. During the same quarter in the prior year, the business earned $1.90 earnings per share. As a group, equities analysts forecast that BioNTech SE will post -3.88 earnings per share for the current year.
Wall Street Analyst Weigh In
A number of equities research analysts recently issued reports on the company. BMO Capital Markets increased their price target on BioNTech from $130.00 to $143.00 and gave the stock an "outperform" rating in a research report on Tuesday, March 11th. Citigroup assumed coverage on shares of BioNTech in a research report on Thursday, March 13th. They set a "buy" rating and a $145.00 price objective for the company. Morgan Stanley decreased their target price on shares of BioNTech from $145.00 to $139.00 and set an "overweight" rating on the stock in a report on Tuesday, March 11th. Canaccord Genuity Group reaffirmed a "buy" rating and set a $171.44 price target on shares of BioNTech in a report on Tuesday, March 11th. Finally, HC Wainwright decreased their price objective on shares of BioNTech from $150.00 to $145.00 and set a "buy" rating on the stock in a research note on Tuesday, April 1st. Three investment analysts have rated the stock with a hold rating, fourteen have issued a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and an average price target of $143.44.
Read Our Latest Stock Report on BNTX
About BioNTech
(
Free Report)
BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.
Featured Articles
Before you consider BioNTech, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and BioNTech wasn't on the list.
While BioNTech currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
